Understanding the impact of Medical Affairs efforts is more important than ever. We are at a critical moment in our industry, in which the imperative to demonstrate how our tactics and activities ladder up to true impact for HCPs and patients has never been greater. Yet, defining and evaluating impact in the setting of Medical Affairs remains uniquely challenging. Join us as we discuss key considerations for driving our function forward on impact, initiating conversations on impact, and practical considerations for improving the evaluation of impact.
Learning Objectives:
- Define the principles of impact in Medical Affairs and consider the role of metrics and KPIs in impact assessment.
- Explore approaches to impact in different settings: the industry (biotech to big pharma), disease states (rare to more prevalent), and therapeutic technologies (e.g., gene therapy and wearables).
- Generate insights on the practical adoption of impact in Medical Affairs’ strategic and tactical approaches.
- Consider the importance and role of Medical Affairs as a key driver of impact and its role within the cross-functional team.

Moderator: Ailsa Stewart
Executive Director, Medical Affairs at HCG
Medical Affairs Professional Society
Speaker: Bryan Sepulveda
Senior Director, Global Medical Affairs Lead at Sirtex
Medical Affairs Professional Society
Speaker: Veena Narayan
Medical Director – Amyloidosis, Medical Affairs at Ionis Pharmaceuticals, Inc.
Medical Affairs Professional Society
Speaker: Ian Winburn
Chief Medical Affairs Officer – Specialty Care at Pfizer
Medical Affairs Professional Society